A scalable starting point for macrophage-based immunotherapy
A research team led by USC Stem Cell says it has found a way to create a renewable, expandable source of immune progenitor cells that could make a new class of cell therapies easier to manufacture at scale. The work, published in Cell, focuses on granulocyte-monocyte progenitors, or GMPs, which give rise to macrophages and other closely related immune cells.
That matters because macrophages have drawn growing interest as potential cancer-fighting therapies. Unlike T cell therapies that attack specific targets in one way, macrophages can engulf abnormal cells and help coordinate wider immune activity. The difficulty has been practical as much as biological: researchers need a dependable source of cells that can be expanded in the lab, modified for therapy, and still behave as intended when used against disease.
The USC-led paper argues that GMPs could become that source. According to the researchers, the cells can be extensively expanded under laboratory conditions while preserving their identity and their ability to generate functional immune cells. The team also showed that the progenitors can be engineered to target specific cancer markers and to help stimulate broader immune responses.
Why the finding stands out
The study challenges a longstanding assumption in blood and immune cell biology. Self-renewal, the ability to keep dividing while maintaining a stable cellular identity, is usually treated as a defining feature of hematopoietic stem cells. Those stem cells sit high in the blood-forming hierarchy and can give rise to many different blood and immune cell types.
By contrast, GMPs are progenitor cells. They are more specialized and already committed to producing a narrower set of immune descendants, including macrophages. The prevailing view has been that this kind of commitment comes with a tradeoff: progenitor cells lose the capacity for long-term self-renewal.
The USC team reports that this tradeoff is not absolute. Under the right conditions, the researchers found that GMPs can continue dividing extensively while retaining both their identity and their capacity to produce functional immune cells. If that result proves robust across additional testing and development, it could reshape how cell therapy developers think about manufacturing pipelines.
Instead of relying on a limited supply of starting cells, researchers could work from a platform designed to be both scalable and engineerable. That combination is especially important for therapies intended to move beyond bespoke, patient-specific production and toward off-the-shelf use.
From proof of concept to platform
The paper is titled Expansion and CAR Engineering of Granulocyte-Monocyte Progenitors for Cellular Immunotherapy, which points to the study’s translational ambition. The researchers did not simply expand GMPs; they also engineered them, including in ways meant to improve their ability to recognize cancer-related targets.
In the source report, the team describes engineered immune cells attacking breast cancer cells. The featured cells are genetically engineered macrophages designed to selectively recognize, engulf, and destroy those cancer cells. That example positions the platform squarely inside the rapidly evolving field of cellular immunotherapy, where the central question is not only whether immune cells can be trained to attack tumors, but whether they can be produced reliably enough to become practical medicines.
Macrophage-based therapy has attracted interest because macrophages operate differently from better-known T cell approaches. They can directly consume target cells, but they can also alter the tumor environment and influence other immune actors. In principle, that broader role could make them useful against solid tumors, an area where some immune therapies have had a harder time delivering consistent results.
The manufacturing barrier, however, has limited progress. A renewable progenitor platform could help address that bottleneck by providing a repeatable upstream source for downstream immune cell products.
What USC is claiming
Qi-Long Ying, professor of stem cell biology and regenerative medicine at the Keck School of Medicine of USC and the paper’s corresponding author, said the study establishes what the team sees as a scalable and engineerable GMP platform for cellular immunotherapy. In the source material, Ying also frames the work as having implications beyond cancer treatment, extending into stem cell biology itself.
That broader claim rests on the finding that self-renewal can be maintained in a progenitor cell type already committed to a specific developmental path. If supported by follow-on work, that would add nuance to the traditional distinction between stem cells and progenitors. It suggests that, under defined conditions, some progenitors may offer more manufacturing flexibility than the field once assumed.
For therapy development, the practical implication is straightforward: a committed progenitor that can still self-renew could be an attractive compromise between versatility and control. Stem cells are powerful but can be harder to direct cleanly. Fully mature immune cells may be easier to understand functionally, but they are often more limited as a scalable starting material. GMPs, in this framing, could sit in a productive middle ground.
What comes next
The report does not present this as a finished treatment ready for clinical use. It presents a platform and a manufacturing concept, supported by a peer-reviewed publication in a major journal. The next questions are the ones that typically determine whether a cell-therapy advance becomes a product candidate: how consistently the cells can be produced, how they behave across disease settings, how durable and controllable their anti-tumor activity is, and how safely they can be engineered for human use.
Even so, the work speaks to one of the biggest structural issues in advanced medicine. Cell therapies often show promise in principle but remain difficult to industrialize. A renewable, expandable source of macrophage progenitors would not by itself solve every problem, but it could reduce one of the field’s core constraints.
That is why the result is notable. It is not just another cancer-immunotherapy claim about what immune cells might do in a dish. It is also a claim about supply: where the cells come from, how many can be made, and whether developers can build a repeatable process around them. If that platform holds up, it may help move macrophage therapies closer to the off-the-shelf model that has long been a goal across regenerative medicine and oncology.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
